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ABSTRACT
Pro-oxidative stressors can suppress host immunity due to their ability to 
generate oxidized lipid agonists of the platelet-activating factor-receptor (PAF-R). 
As radiation therapy also induces reactive oxygen species, the present studies 
were designed to define whether ionizing radiation could generate PAF-R agonists 
and if these lipids could subvert host immunity. We demonstrate that radiation 
exposure of multiple tumor cell lines in-vitro, tumors in-vivo, and human subjects 
undergoing radiation therapy for skin tumors all generate PAF-R agonists. Structural 
characterization of radiation-induced PAF-R agonistic activity revealed PAF and 
multiple oxidized glycerophosphocholines that are produced non-enzymatically. In 
a murine melanoma tumor model, irradiation of one tumor augmented the growth 
of the other (non-treated) tumor in a PAF-R-dependent process blocked by a 
cyclooxygenase-2 inhibitor. These results indicate a novel pathway by which PAF-R 
agonists produced as a byproduct of radiation therapy could result in tumor treatment 
failure, and offer important insights into potential therapeutic strategies that could 
improve the overall antitumor effectiveness of radiation therapy regimens.
INTRODUCTION
Radiotherapy (RT) is an important modality in the 
management of many types of cancer [1]. Treatment plans 
with ionizing radiation (IR) are designed by radiation 
oncologists to selectively kill tumor cells, and spare 
normal tissue. IR damages a wide variety of targets in 
tumor cells through direct and indirect effects, but damage 
to DNA and/or DNA replication/repair machinery play 
major roles in radiation-induced cell death [1]. One of the 
consequences of IR is the generation of reactive oxygen 
species (ROS) [2-3]. Several groups, including ours, have 
demonstrated suppression of host immunity in the presence 
of various pro-oxidative stressors through a mechanism 
involving the lipid mediator Platelet-activating Factor 
(1-alkyl-2-acetyl-glycerophosphocholine; PAF) [4-8]. Pro-
oxidative stressors including aromatic hydrocarbons found 
in jet fuel, chemotherapeutic agents, cigarette smoke, and 
ultraviolet B (UVB) radiation generate ROS that can act 
directly on glycerophosphocholines (GPC) to produce 
oxidized GPC (ox-GPC) which are potent PAF-receptor 
(PAF-R) agonists [9-14]. Structural studies using mass 
spectrometry have identified more than a dozen ox-GPC, 
including native PAF itself [15-18]. Yet, there is evidence 
for hundreds of these biologically active compounds [18-
19] that have by-passed the tightly controlled enzymatic 
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process of PAF production [20]. Like native PAF, these 
Ox-GPCs are metabolically unstable and their half-lives 
in tissue/blood are measured in minutes [20-21].
The mechanisms for PAF-R-mediated immuno-
suppression have been characterized using murine 
models [4-8]. Using UV light as the prototype, UVB 
irradiation of skin results in the formation of PAF/ox-
GPCs [15]. These ox-GPCs act upon the mast cell PAF-R 
inducing its translocation to draining lymph nodes which 
then, through cyclooxygenase-2 (COX-2) dependent 
manner [22], generate regulatory T cells (Tregs) that 
are the effector cells for immunosuppression [8]. 
PAF-R agonists produced in response to UVB/standard 
chemotherapeutic agents can inhibit tumor immunity 
via PAF→COX-2→Treg process, which is blocked by 
antioxidants, COX-2 inhibitors, neutralization of IL-10, 
and depletion of Tregs [23-24].
Since IR can induce ROS, the present studies were 
designed to test whether IR doses typically administered 
in radiotherapy clinic can generate PAF-R agonists and 
determine their structural composition. Moreover, these 
studies sought to define whether IR-generated PAF-R 
agonists impact radiotherapy effectiveness. These studies 
provide the first evidence that IR induces high levels of 
PAF and ox-GPC PAF-R agonists that block anti-tumor 
immunity via systemic PAF-R signaling in a process that 
can be ameliorated via COX-2 inhibitors.
RESULTS
Ionizing radiation generates PAF-R agonists 
in melanoma cells in a process blocked by 
antioxidants
The first studies were designed to test whether IR 
can induce PAF-R agonist formation in melanoma cells. 
As multiple GPC species can act as PAF-R agonists, 
we quantified total PAF-R biochemical activity in lipid 
extracts from murine B16F10 melanoma cells following 
treatment with 5 Gy of IR as measured by intracellular 
calcium mobilization responses in Fura-2-loaded PAF-
R-expressing KBP cells [7-8, 25]. Note that the amount 
of total PAF-R agonistic activity is defined as the Ca2+ 
mobilization peak height of normalized lipid extract as a % 
of the peak height from excess (1μM) of the metabolically 
stable PAF-R agonist carbamoyl-PAF (CPAF). Use of 
this semi-quantitative cellular biochemical assay allows 
all PAF-R activity to be measured. As shown in Figure 
1A&1B, lipid extracts from B16F10 melanoma cells 
treated with IR induced PAF-R agonistic activity only in 
KBP but not in PAF-R-negative KBM cells. IR treatment 
generated PAF-R agonistic activity in a dose-dependent 
manner which appeared maximal at 10Gy (Figure 1C). 
Time course studies revealed that IR-generated PAF-R 
agonistic activity was detected almost immediately 
in B16F10 cells and the activity remained elevated 
above base-line levels at 8h post-treatment (Figure 1D). 
Similar to our published findings examining PAF-R 
biochemical activity generated in human epithelial tumor 
cells or human skin in response to UVB [15, 17, 26], 
preincubation of melanoma cells with antioxidants vitamin 
C or N-acetylcysteine (NAC) blocked IR-generated PAF-R 
agonistic activity (Figure 2). These studies indicate that 
IR-generated PAF-R agonistic activity in B16F10 cells are 
in part through a process that involves ROS.
Structural identification of IR-generated PAF-R 
agonists in B16F10 cells and comparison with 
PAF-R agonistic activity
PAF-R agonists can be produced both enzymatically 
as well as via non-enzymatic free radical processes [9-
11,13, 14-15, 20]. Interestingly, the majority of ox-GPCs 
have not been structurally characterized [16, 18-19]. To 
define if non-enzymatic ox-GPC PAF-R agonists are 
formed in response to IR, we used mass spectrometry-
based structural studies using deuterium-labeled internal 
standards as reported [17]. In these experiments, a part of 
each sample was subjected to mass spectrometry and part 
was tested for PAF-R agonistic activity by measurement of 
IL-8 release in KBP cells. The advantage of the KBP-IL-8 
assay is that the amount of IL-8 release can be directly 
compared to a dose-response curve of PAF. As shown in 
Table I, 1h after irradiation of B16F10 cells in-vitro with 
10Gy resulted in the formation of both PAF, 1-palmitoyl 
2-acetyl GPC (acyl PAF) and multiple ox-GPCs compared 
to sham-irradiated cells. However, no differences in 
the levels of the inactive PAF-precursor lyso-PAF 
(1-hexadecyl-2-lyso GPC) between sham-irradiated and 
irradiated cells were noted (Table I).
Approximately 1/10th of the lipid extracts were 
tested for PAF-R agonistic activity by incubation with 
KBP cells and IL-8 measured in the supernatant 6h later by 
ELISA as a surrogate for PAF-R activation [27]. As shown 
in Figure 3, PAF induced IL-8 formation in KBP cells in a 
dose-dependent manner. There was basal PAF-R agonistic 
activity in lipid extracts derived from unirradiated (sham) 
B16F10 cells similar to that observed in cells treated with 
vehicle and at lower doses of PAF (Figure 3). However, 
high levels of IL-8 were measured in the supernatants of 
KBP cells treated with lipid extracts taken from B16F10 
cells exposed to IR (Figure 3). As expected, these lipid 
extracts did not generate increased levels of IL-8 release 
in KBM cells (data not shown). When these lipid extract-
derived IL-8 PAF-R activities were compared with known 
PAF, we estimated the complex mixture of GPC in the 
lipid extracts contained the equivalent of 409 pg of PAF 
per 106 cells. However, mass spectrometry studies indicate 
that ~110pg of PAF per 106 cells were found in the lipid 
extracts (Table I). These studies suggest that a significant 
amount of the IR-induced PAF-R agonistic activity resides 
in non-PAF ox-GPCs.
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Ionizing radiation generates PAF-R agonists in 
multiple tumor cell types in-vitro and in-vivo
The next studies were designed to test if IR can 
generate PAF-R agonists in other tumor types both in-
vitro and in-vivo. For these studies we used tumor types 
syngeneic to C57BL/6 mice. As shown in Figure 4A, 
treatment of Lewis lung carcinoma (LLC1) or T-cell 
lymphoma (EL4) cells generated significant levels of 
PAF-R agonistic activity. Of note, irradiation of primary 
cultures of human fibroblasts yielded very little PAF-R 
agonistic activity (Figure 4A). To define if radiotherapy of 
tumors in-vivo generated PAF-R agonists, we implanted 
5 x 105 B16F10, LLC1, or EL4 tumor cells into both 
hind limbs of C57BL/6 mice. When the tumors reached 
approximately 10mm diameter, the tumor on one limb was 
treated with 5Gy, while the other tumor was shielded from 
IR (left untreated). One hour following irradiation, the 
mice were euthanized, and the tumors dissected, weighed, 
and lipid extract assayed for PAF-R agonistic activity 
using our KBP Ca2+ assay. In some experiments, normal 
non-tumor-bearing skin was treated with a similar dose of 
IR and used as a control. As shown in Figure 4B, radiation 
exposure resulted in an increased level of PAF-R agonistic 
activity in various tumor types. However, IR of normal 
skin resulted in only negligible PAF-R agonistic activity.
We have reported that intratumoral chemotherapy of 
B16F10 tumors also generates PAF-R agonistic activity 
[24]. To compare the levels of PAF-R agonists generated 
between intratumoral chemotherapy and IR, we subjected 
mice previously implanted with two B16F10 tumors 
to intratumoral injections of etoposide (36mg/kg) or 
melphalan (15mg/kg) to one tumor with the other tumor 
treated with 50 μl of saline vehicle [24]. After 1h, the 
tumors were harvested and lipid extracts tested for PAF-R 
agonistic activity as outlined above. As depicted in Figure 
4B, the levels of PAF-R agonistic activity generated by 
intratumoral chemotherapy resembled those tumors treated 
Figure 1: Irradiation of melanoma cells generates PAF-R agonists. B16F10 cells were sham-irradiated (e.g. unirradiated) or 
exposed to ionizing radiation (IR; radiation therapy [RT]). A, B. Examples of intracellular Ca2+ mobilization responses in B16F10 cells that 
were exposed to 5 Gy IR. After 1h, lipids were extracted and PAF-R agonistic activities were measured with Ca2+ mobilization responses 
in FURA-2-labelled PAF-R-expressing KBP (A) or PAF-R-negative KBM (B) cells. KBM cells treated with 1μM endothelin 1 (ET-1) 
served as positive control. C. Dose-responsiveness of IR-induced PAF-R agonistic activity. B16F10 cells were treated with various IR 
doses and harvested 1h post-radiation. D. Time course of IR-generated PAF-R agonistic activity. B16F10 cells were irradiated with 10Gy 
and harvested at various times. Data are mean±SE and expressed as % maximum (1 μM CPAF) intracellular Ca2+ response in KBP cells 
from at least three separate experiments.
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with IR. Again, subcutaneous injection of chemotherapy 
into normal skin did not generate appreciable amounts 
of PAF-R agonistic activity (Figure 4B). These studies 
indicate that IR generates PAF-R agonists in diverse tumor 
types but not in normal skin.
PAF-R activation diminishes effectiveness of IR 
in a COX-2-dependent process
Given our previous findings that intratumoral 
chemotherapy of one tumor modulates the growth of 
a second tumor in a PAF-R-dependent fashion in a 
process involving Tregs and COX-2 metabolites [24], 
we tested if irradiation of one tumor can modulate the 
growth of a second tumor. Our protocol was modified 
in that WT and PAF-R-deficient (Ptafr-/-, PAFR-KO) 
mice underwent implantation with B16F10 tumors on 
both dorsal hindquarters (2 tumors/mouse). The left 
flank tumors were either sham-irradiated or irradiated 
with 5Gy starting at day 6 of tumor implantation and 
repeated every 2-3 days until the termination of the 
experiment, while the other (right flank) tumors left 
undisturbed (shielded). Irradiation of one tumor resulted 
in an enhanced growth of the second (undisturbed) 
tumor in WT compared with Ptafr-/- hosts (Figure 5). 
Though irradiation resulted in growth inhibition of the 
treated left flank tumors, loss of host PAF-R function 
exerted no perceptible effect on the left flank tumor 
growth characteristics (Supplementary Figure S1). To 
assess whether COX-2 is crucial for PAF-R mediated 
augmentation of tumor growth, WT mice were 
implanted with two B16F10 tumors and then treated 
with intraperitoneal injections of the COX-2 inhibitor 
(SC-236) or saline vehicle starting at day 0 and every 
3 days afterwards. As shown in Figure 6, the COX-2 
inhibitor blocked the tumor growth enhancing effects 
of IR on the second tumor. We did not note any effects 
of COX-2 inhibitor exposure on the irradiated (left) 
tumor (data not shown). These studies reveal that IR 
generates adequate levels of PAF-R agonists to augment 
tumor growth. Moreover, this process was attenuated by 
pharmacologic inhibition of COX-2.
Figure 2: Effect of antioxidants on IR-mediated PAF-R agonists generation. B16F10 cells were preincubated with antioxidants, 
vitamin C (2.5 mM) or N-acetyl cysteine (5 mM) for 1 h following irradiation with 10 Gy.Lipids were extracted and PAF-R agonistic 
activities were measured with Ca2+ mobilization responses in FURA-2-labelled PAF-R-expressing KBP cells. The data are the mean ± SE 
percentage of peak intracellular calcium response (normalized to 1 μM CPAF). * Denotes statistically significant (P < 0.05) fold changes 
from vehicle, and antioxidants alone-treated cells.
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Table I: Effect of IR on levels of PAF and ox-GPCs in B16F10 tumor cells
Glycerophosphocholine Control Mean (SEM) RT Mean (SEM)
 PAF 5.2 (2.9) 114(11)
PAcPC 48 (18) 955(125)
BPAF 0.2 (0.2) 9.6 (2.4)
 PBPC 5.8 (3) 211 (43)
 PPrPC 0.9 (0.5) 2.4 (0.9)
 PHPC 0 (0) 15.9 (7.1)
AzPAF 7.7 (5.6) 3.2 (3.2)
 PAzPC 235 (148) 143 (70)
 OVPAF 0 (0) 0 (0)
POVPC 7.1 (2.0) 5.4 (0.3)
(Continued )
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Figure 3: Ionizing Radiation of B16F10 cells generates PAF-R agonistic activity as measured by IL-8 production in 
KBP cells. B16F10cells were sham-irradiated or irradiated with 10Gy IR. After 1 h of incubation, lipids were extracted and added to the 
culture of KBP cells. Following 6 h of incubation, supernatant was removed and IL-8 release was measured by ELISA to test for the PAF-R 
agonistic activity. In addition, KBP cells were incubated with various doses of PAF or vehicle and used as positive and negative controls. 
This experiment was performed in triplicate and repeated three times. * Denotes statistically significant (P < 0.05) changes from vehicle 
or sham-treated cells.
Glycerophosphocholine Control Mean (SEM) RT Mean (SEM)
PONPC 11.5 (4.2) 11.7 (0.5)
Lyso-PAF 54 (7) 56 (16)
B16F10 cells were irradiated with 10Gy or sham-irradiated in vitro. After 1 h of incubation, lipid extracts were analyzed 
by HPLC/MS/MS using deuterium-labeled internal standards to quantify PAF and Ox-GPC. Data are pg/106 cells from 
at least three separate experiments. The names of each ox-GPCs in this table are: PAF, platelet-activating factor; PAcPC, 
1-palmitoyl-2-acetyl-GPC; BPAF, 1-O-hexadecyl-2-butanoyl-GPC; PBPC, 1-palmitoyl-2-butanoyl-GPC; PPrPC, 
1-palmitoyl-2-propanoyl-GPC; PHPC, 1-palmitoyl-2-hexanoyl-GPC; AzPAF, 1-O-hexadecyl-2-azeleoyl-GPC; PAzPC, 
1-palmitoyl-2- azeleoyl-GPC; OVPAF, 1-O-hexadecyl-2-(5)oxo-valeroyl-GPC; PONPC, 1-palmitoyl-2-oxononanoyl-GPC; 
Lyso-PAF, inactive precursor of PAF.
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Identification of PAF-R agonists produced in 
response to radiotherapy of cutaneous tumors  
in humans
To test whether IR exposure results in PAF-R 
agonists production in humans, we identified subjects 
who were receiving radiation treatments for different types 
of tumors. Following informed consent, a 2 mm punch 
biopsy was obtained from a tumor before RT. Immediately 
following the RT procedure, a second 2 mm punch biopsy 
was obtained from the tumor. The biopsies were subjected 
to lipid extraction and 1/10th of the extracts tested for 
PAF-R agonistic activity via our KBP Ca2+ assay, with the 
remainder subjected to mass spectrometry to quantify PAF 
Figure 5: Localized irradiation augments the growth of untreated B16F10 melanomas in a PAF-R-dependent manner. 
A. Groups of 6-7WT and Ptafr-/- (PAFR-KO) mice were implanted with PAF-R deficient B16F10 tumors on both the dorsal hind flanks 
(day 0). Six days later (and q 2-3days afterwards) left side tumors were sham-irradiated or irradiated with 5Gy of IR. The right side tumors 
left untreated (shielded). Tumor growth was measured over time and tumor volume was calculated. The data are mean±SE of tumor volume 
of untreated tumors. B. Tumor volume of untreated tumors at day 15 from sham and IR-treatment. There were significant differences in 
the growth of RT-treated *(P<0.05) or $ (P <0.1) but not sham-treated tumors (ns= non-significant). This experiment was repeated with 
additional 6-7 mice/group with similar results.
Figure 4: Effects of IR on PAF-R agonists production from several tumor types. A. Murine B16F10, LLC1, EL4 and human 
fibroblasts were treated with sham or 10Gy IR. B. WT mice were implanted with B16F10, LLC1, EL4 cells (0.5x106) into both hindlimbs. 
Once tumors reached 10mm size, one tumor was treated with 5Gy IR or etoposide (ETOP; 36mg/kg) or melphalan (MELPH; 15mg/kg) 
and other tumor with sham or vehicle (100μl PBS). Following 1h incubation (A&B) cells and tumors harvested and lipids extracts were 
tested for PAF-R agonist activity. Human fibroblasts (in-vitro) and normal skin (in-vivo) treated ± IR or chemotherapeutic agents were used 
as controls. The data are mean±SE percentage of peak calcium response (normalized to CPAF) from 3 separate experiments (A) and 4-6 
separate tumors (B).
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and other structurally known GPCs. As shown in Table II, 
all of the four irradiated tumor samples contained PAF-R 
agonistic activity, which ranged from 2-24X baseline 
levels. Structural characterization of the samples using 
mass spectrometry identified elevated levels of PAF 
and several ox-GPC species. Clinical pictures of two of 
the subjects, a large basal cell carcinoma and a bladder 
carcinoma, are found in Supplementary Figure S2. These 
studies indicate that clinical RT exposure can generate 
PAF-R agonists in human tumors.
DISCUSSION
While radiotherapy is commonly used to treat human 
malignancies, it is not considered a good treatment option 
as a single agent for malignant melanoma [1]. The present 
studies describe a previously unappreciated mechanism by 
which IR exposure results in immunosuppression [28-29]. 
These existing data support the model that PAF and ox-
GPC PAF-R agonists produced in part due to ROS from IR 
can exert systemic immunosuppressive effects.
Oxidation of esterified fatty acyl residues introduces 
oxy functions, rearranges bonds and fragments carbon-
carbon bonds by ɷ-scission that generate a myriad of 
phospholipid reaction products including PAF-R agonists 
[14]. In contrast to tightly controlled enzymatic pathways 
for PAF biosynthesis, large amounts of numerous ox-
GPC PAF-R agonists can be produced non-enzymatically. 
Though this has been an area of intensive study for 
multiple groups including ours, only a small number of 
the structures of these ox-GPCs have been elucidated 
[17, 24]. The present studies not only demonstrate that 
IR-generated PAF-R agonistic activity is diminished 
by antioxidants, but structural characterization of this 
activity reveals ox-GPCs known to be produced non-
enzymatically. By comparison of PAF produced versus 
non-PAF agonistic activity (Figure 3), it appears that 
majority of IR generated PAF-R agonists are due to ox-
GPCs, not enzymatically produced PAF. These findings 
are consistent with IR being a potent pro-oxidative 
stressor. It is likely that tumor cellular membranes serve 
as the source of PAF and oxidized phospholipids from 
the IR and are thus the source of RT-mediated PAF-R 
agonist formation in the experimental murine and human 
models used. This finding is supported by the negligible 
production of PAF-R agonistic activity found in normal 
murine skin following RT. However, it appears that IR 
does result in at least some PAF-R agonist formation in 
human skin, as has been reported using a rodent model of 
IR of skin window chambers and very sensitive PAF-R 
assay of leukocyte adhesion in the presence/absence of a 
PAF-R antagonists [45].
Radiotherapy has been demonstrated to exert an 
immunostimulatory effect in both preclinical as well as 
human studies [30-32]. This “abscopal effect” is well-
known to radiation biologists and consists of shrinkage 
of other tumors which are not in the radiation field during 
RT. The mechanisms for this abscopal effect and why it 
Figure 6: Role of COX-2 in RT-mediated augmentation of tumor growth. A. Groups of 6-13 WT mice were implanted with 
PAF-R deficient B16F10 tumors on both the dorsal hind flanks (day 0). Following tumor implantation (day 0) and every 3 days mice were 
i.p. injected with or without COX-2 inhibitor, SC-236 (200 ng). After 6 days of tumor implantation when mice developed palpable tumors 
(10mm), left side tumors were irradiated with 5Gy of IR and repeated at every q2-3 days and right side tumors left untreated. Tumor 
growth was assessed over time and tumor volume was calculated. B. A representative tumor volume data at day 15 (right side) in all the 
experimental groups. The data depicted are the mean ± SE of tumor volume of untreated tumors over time. Statistical significant differences 
were noted in the growth of RT-treated *(P<0.05) or $ (P<0.1) but not sham-treated tumors (ns denotes non-significant).
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is seen only in some cases and not others are not entirely 
clear. It is possible that the generation of PAF-R agonists 
as a by-product of RT could provide an explanation 
for why RT-mediated abscopal effects are not seen 
consistently in the clinic. It should be noted that in our 
experimental conditions we did not observe an abscopal 
effect. Interestingly, our previous murine models have 
suggested that only certain tumors (B16F10, LLC1), but 
not others (EL4) are affected by exogenous PAF agonists 
[23-24, 33-34]. Moreover, PAF and ox-GPC PAF-R 
agonist accumulation can be affected by multiple factors. 
These include diet, as Western diet with high levels of 
arachidonic acid can provide high levels of PAF-R agonist 
precursor 1-alkyl GPC species with highly unsaturated 
fatty acids at the sn-2 position. In addition, these bioactive 
lipids can be affected by levels of the PAF- and ox-
GPC metabolizing enzyme serum PAF-acetylhydrolase 
(PLA2G7). Of note, there are both genetic and acquired 
deficiencies of this enzyme which could possibly play an 
important role in RT clinical responses [35].
Tumor resistance to therapeutic treatments such as 
RT and chemotherapy is an important clinical problem and 
is an area of active study. In contrast to cellular resistance 
to the effects of these agents, the present studies using 
RT and our previously reported ones using chemotherapy 
and UVB describe a novel mechanism by which these 
modalities could subvert anti-tumor immunity. Indeed, our 
studies using UVB and chemotherapy provide evidence 
implicating anti-tumor immunity, in particular Tregs in 
PAF-mediated effects on B16F10 tumor growth [23-24]. 
First, PAF effects are not seen when tumors are placed 
in immunodeficient mice [23]. Second, use of PAF-R-
negative B16F10 cells transduced with functional PAF-Rs 
implanted in WT vs Ptafr-/- hosts have confirmed that the 
PAF-R mediating the response is on the host, not tumor. 
Finally, use of neutralizing antibodies against IL-10 or 
depleting Tregs both block PAF-mediated augmentation 
of experimental tumor growth. Our findings fit with the 
report that high doses of IR in murine tumor models of 
RT generate high levels of Tregs, a finding not seen after 
exposure to low doses of IR [36].
Exogenous pro-oxidative stressors ranging from 
aromatic hydrocarbons to cigarette smoke to UVB radiation 
have been shown to induce systemic immunosuppression 
via PAF-R signaling which is blocked by antioxidants [5, 
7-8, 10]. Apoptotic cells generate PAF and contribute to 
melanoma tumor progression via PAF-R activation [37]. 
The production of PAF-R agonists from these various 
agents begins a cascade of events leading to systemic 
immunosuppression. The cytokines which appear to be 
critical for the immunosuppression include IL-10 and 
COX-2-generated eicosanoids [4, 6, 8]. Mast cells and 
Tregs are also implicated in PAF-R-dependent systemic 
immunosuppression [8, 22, 38]. The present studies 
demonstrating that COX-2 inhibitor blocks IR-mediated 
augmentation of experimental tumor growth are not only 
consistent with previous studies characterizing the role of 
this eicosanoid-generating enzyme in PAF-mediated systemic 
immunosuppression [4, 6, 8] they also provide the rationale 
for future studies testing the ability of COX-2 inhibitors to 
enhance the effectiveness of RT. It should be noted that COX-
2 inhibitors have been shown to exert not only radioprotective 
properties on the host, but can also serve as radiosensitizing 
agents [39-40]. Moreover, COX-2 inhibitors also exert direct 
antitumor effects in a variety of tumor types [41-42].
In summary, the present studies provide the first 
evidence that IR can generate PAF and that PAF-R 
signaling can inhibit RT effectiveness. In contrast to 
resistance mechanisms that are applicable at the tumor 
cell level, this process is likely due to the subversion 
of host tumor immunity. That RT generates PAF-R 
agonists in humans is suggestive that this novel 
TABLE II: Identification of PAF and ox-GPCs in human skin following RT
Tumor 
Type
Treatment PAF PAcPC BPAF PBPC GPAF PHPC AzPAF PAzPC OVPAF ONPAF POVPC PONPC Ca2+ 
Response
BCC #1 Pre-RT 3216 83 53 48 170 ND 6615 28255 7 6 6 15 25%
RT (0.3 Gy) 4583 242 79 163 482 ND 10345 50059 27  16 7 64 78%
BCC #2 Pre-RT 2633 45 30 30 109 ND 3623 18631 3 8 6 27 30%
RT (0.3 Gy) 5950 59 117 203 396 4 9713 39834 12  36 9 82 62%
Bladder 
Ca Pre-RT 2504 140 36 35 98 1 2991 15623 10 9 3 27 8%
RT (0.7 Gy) 7410 376 205 309 534 5 10240 43593 15  37 7 69 22%
Pseudo- Pre-RT 23 72 15 23 2 7 424 NM 26 280 NM 1328 2%
lymphoma RT (0.2 Gy) 3086 1031 96 127 25 28 1663 NM 103 832 NM 4511 48%
Values of PAF and other GPC are pg per 90% of lipid extracts from 2 mm punch biopsy specimen; Ca2+ response denotes % of peak Ca2+ mobilization 
response compared to 1 μM CPAF in FURA-2-loaded KBP cells from 5% of the biopsy specimen. The names of each ox-GPCs in this table are: PAF, 
platelet-activating factor; PAcPC, 1-palmitoyl-2-acetyl-GPC; BPAF, 1-O-hexadecyl-2-butanoyl-GPC; PBPC, 1-palmitoyl-2-butanoyl-GPC; GPAF, 
1-O-hexadecyl-2-glutaroyl-GPC; PHPC, 1-palmitoyl-2-hexanoyl-GPC; AzPAF, 1-O-hexadecyl-2-azeleoyl-GPC; PAzPC, 1-palmitoyl-2- azeleoyl-GPC; 
OVPAF, 1-O-hexadecyl-2-(5)oxo-valeroyl-GPC; ONPAF, 1-O-hexadecyl-2-oxononanoyl-GPC; POVPC, 1-palmitoyl-2-(5)oxo-valeroyl-GPC; PONPC, 
1-palmitoyl-2-oxononanoyl-GPC.
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pathway could have tremendous clinical significance. 
Since this process involves the pro-oxidative qualities 
of RT and is potentially neutralized by antioxidants, 
with downstream effects susceptible to COX-2 
inhibition, these studies could provide the impetus for 
future studies to define the clinical significance of this 
novel pathway in humans.
MATERIALS AND METHODS
Reagents and cell lines
All chemicals were obtained from Sigma-Aldrich (St. 
Louis, MO) unless indicated otherwise. Murine melanoma 
B16F10, lung carcinoma Lewis Lung Carcinoma (LLC1) 
and T cell lymphoma cell line EL4 cells were obtained from 
ATCC (Boston, MA) were grown in DMEM high glucose 
media with 10% FCS as described [23-24, 33-34]. PAF-R-
negative KB cells were rendered PAF-R-positive (KBP) 
by transducing the MSCV2.1 retrovirus encoding the 
human leukocyte PAF-R and PAF-R-deficient (KBM) by 
transducing with the vector alone and grown in DMEM high 
glucose media with supplements as described previously 
[25]. Primary cultures of human fibroblasts were obtained 
from neonatal discarded foreskins and grown as described 
[43]. Cell lines were grown to approximately 80-90% 
confluence in 10 cm dishes, and washed three times with 
Hanks Balanced Salt Solution (HBSS) and then incubated 
with 2 ml of pre-warmed (37 °C) HBSS with 10mg/ml fatty 
acid-free BSA with 2 μM of the serine hydrolase inhibitor 
pefabloc. B16F10 melanoma cells were radiated with 
multiple doses of ionizing radiation and incubated at various 
time points as given in the figure legends. Cell irradiation 
studies were conducted using a 160-kVp Faxitron X-ray 
machine. Settings for the machine were as follows: 0.5 mm 
Al filter, d = 33 cm, and dose rate of 251.7 cGy/min. In 
some experiments, antioxidants were preincubated for 60 
min before addition of chemotherapeutic agents or DMSO 
(0.5%) vehicle. The incubations were quenched by addition 
of 2 ml of ice-cold methanol followed by methylene 
chloride, and lipids extracted as described [7-8].
Mice
Female C57BL/6-wild type mice (PAF-R 
expressing; age 6-8 week) were purchased from The 
Charles River Laboratories. Age-matched female PAF-
R-deficient (Ptafr-/-) mice on a C57BL/6 background, 
generated as described [44], were a kind gift of Professor 
Takao Shimizu (Department of Biochemistry, University 
of Tokyo). All mice were housed under specific pathogen-
free conditions and all procedures were approved by the 
Institutional Animal Care and Use Committee of Indiana 
University School of Medicine (IUSM).
Measurement of PAF-R agonists
Calcium mobilization studies
The presence of systemic PAF-R agonists in lipid 
extracts derived from IR and chemotherapeutic agent-
treated tumors/cell lines was measured by the ability of 
lipid extracts to induce an intracellular Ca2+ mobilization 
response in PAF-R-expressing KBP cells, but not in PAF-
R-deficient KBM cells as described [7-8, 25].
PAF-R IL-8 release
PAF-R agonistic activity in lipid extracts was also 
measured by measuring IL-8 released into the supernatants 
of KBP vs KBM cells as reported [8].
Mass spectrometry studies
Mass spectrometry was performed on cell lines and 
perfusion samples using the AB Sciex (Foster City, CA) 
triple quadrupole QTRAP® 5500 mass spectrometer, 
equipped with a CTC-PAL autosampler and a Shimadzu 
HPLC as described [17]. Please see Supplementary 
Methods for details.
In-vivo tumor PAF production and growth studies
To determine the ability of RT to produce PAF-R 
agonists, 5x105 B16F10, LLC1 or EL-4 cells (which 
lack functional PAF-R [23-24, 33-34]), were implanted 
subcutaneously into both hind flanks of WT and Ptafr-/- 
mice to produce two tumors followed by treatment with 
or without x-ray. In some studies tumors were injected 
with 50μl of either etoposide (36mg/kg), melphalan 
(15mg/kg), or PBS with 0.5%DMSO vehicle. The mice 
were anesthetized at 1h post-irradiation and tumors 
dissected, weighed, and subjected to lipid extraction.
To determine the ability of IR to modulate 
tumor growth, B16F10 cells were implanted into 
both hindlimbs and the mice were subjected to IR q3 
days starting at day 6. To define the ability of COX-
2 inhibitors to modulate IR-mediated tumor growth, 
SC-236 (200ng) or 100μl PBS were injected i.p. at 
day 0 and every 3 days afterwards [24]. When tumors 
became approximately 10mm in largest dimension, then 
one tumor was treated with radiation, while the other 
tumor was out of the x-ray field and was also shielded 
with lead. Tumors were irradiated with 5 Gy of x-rays 
using a Precision XRAD 320 (North Branford, CT) 
(250 kVP, dose rate of 1.442 Gy/min, 2mm Aluminum 
filter, 50 cm from source). Tumors were treated 
with x-rays 5 different times, with 2-3 days between 
treatments. Tumor growth (major circumference and 
minor circumference) was monitored and measured 
at various times with digital calipers (Mitituyo), and 




Subjects undergoing localized RT for tumors in 
skin and metastasized to the skin (from bladder cancer 
patient) as part of their management were recruited for 
these studies. Following informed consent, a 2mm punch 
biopsy was obtained from the tumor. Following RT (within 
5-10min after treatment), the subject then underwent 
a 2mm punch biopsy from the treated tumor. The 2mm 
punch biopsies were placed immediately in ice-cold 
methanol and lipids extracted using our standard protocol 
[7]. 1/10th of the lipid extract was tested for PAF-R 
agonistic activity using calcium mobilization responses 
in KBP cells compared to CPAF [24]. The rest of the 
lipid extracts were subjected to mass spectrometry [17]. 
The human studies were approved by IUSM Institutional 
Review Boards.
Statistical analysis
For all murine studies, individual experiments were 
performed using at least 6 mice per group and repeated 
as necessary (at least twice) to verify reproducibility 
and provide additional data for analysis. All statistical 
calculations were performed using SAS Version 9.3 and 
R Version 3.2.0. For murine studies, the analysis focused 
at the end of the study (days 15-20), where available. 
For murine and in-vitro data, we used 2 sample t-tests 
to compare two groups at different time points. The 
normality of data and equal variances were checked by 
Shapiro-Wilk’s and Levene’s tests and was a reasonable 
assumption in all cases. To further explore the treatment 
effect during the whole study period and time, we used 
2 way analysis of variance test. The data represent 
mean±SE values. Differences were considered statistically 
significant when P<0.05 and marginally significant when 
P<0.10.
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